19:30 , Jun 15, 2018 |  BC Week In Review  |  Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights...
00:44 , Jan 5, 2018 |  BC Extra  |  Company News

ChemoCentryx gains after EMA validates avacopan MAA

ChemoCentryx Inc. (NASDAQ:CCXI) jumped $2.44 (39%) to $8.63 Thursday after it said EMA validated an MAA for avacopan (CCX168), triggering a $50 million milestone payment from Vifor Fresenius Medical Care Renal Pharma Ltd. ChemoCentryx also...
22:23 , Aug 11, 2017 |  BioCentury  |  Regulation

Foundation for inclusion

Hosting a patient-focused drug development workshop was the National Kidney Foundation Inc. ’s first step in assuming the role of facilitator to collect patient perspectives that will shape R&D for kidney disease. On Aug. 4,...
01:06 , Aug 4, 2017 |  BC Extra  |  Politics & Policy

National Kidney Foundation holding patient-focused meeting with FDA

On Friday, the National Kidney Foundation (NKF) will lead a patient-focused drug development (PFDD) meeting on complement 3 glomerulopathy (C3G), a rare kidney disease, in the hopes of advancing development of innovative treatments for the...
20:29 , Jun 16, 2017 |  BC Week In Review  |  Company News

Vifor Fresenius grants Kissei rights to ANCA-associated AAV candidate avacopan in Japan

Vifor Fresenius Medical Care Renal Pharma Ltd. granted Kissei Pharmaceutical Co. Ltd. (Tokyo:4547) exclusive Japanese rights to develop and commercialize avacopan (CCX168), a candidate to treat antineutrophil cytoplasmic antibody ANCA-associated vasculitis. Vifor Fresenius Medical Care...
19:49 , Feb 17, 2017 |  BC Week In Review  |  Company News

ChemoCentryx, Galenica deal

ChemoCentryx and Galenica’s Vifor Pharma company added rights in Asia and the Middle East to a 2016 licensing deal to commercialize avacopan (CCX168). Vifor now has rights to the compound worldwide outside of the U.S....
21:56 , Dec 30, 2016 |  BC Week In Review  |  Company News

ChemoCentryx, Galenica deal

ChemoCentryx and the Vifor Pharma Ltd. subsidiary of Galenica expanded a 2016 deal to include ChemoCentryx candidate CCX140 . ChemoCentryx granted Vifor exclusive, worldwide rights, excluding the U.S. and China, to CCX140 to treat rare...
00:25 , Dec 23, 2016 |  BC Extra  |  Company News

Vifor, ChemoCentryx expand kidney partnership

ChemoCentryx Inc. (NASDAQ:CCXI) and the Vifor Pharma Ltd. subsidiary of Galenica Ltd. (SIX:GALN) said they will expand their kidney disease partnership to include ChemoCentryx candidate CCX140 , an inhibitor of CC chemokine receptor 2 (...
00:22 , Dec 23, 2016 |  BC Extra  |  Company News

Vifor, ChemoCentryx expand kidney partnership

ChemoCentryx Inc. (NASDAQ:CCXI) and the Vifor Pharma Ltd. subsidiary of Galenica Ltd. (SIX:GALN) said they will expand their kidney disease partnership to include ChemoCentryx candidate CCX140, an inhibitor of CC chemokine receptor 2 (CCR2; CD192)....
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

CCX168: Phase II data

Top-line data from the double-blind, placebo-controlled, North American Phase II CLASSIC trial in 42 patients with newly diagnosed or relapsed AAV showed that twice-daily 10 and 30 mg CCX168 plus standard of care (SOC) were...